Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | EDNRA | P25101 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Para-Nitrosulfathiazole SCHEMBL338503 | 0.96 | ALDH1A1 (0.67) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL8356849 | 0.88 | KMO (0.56) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL848949 | 0.82 | ALDH1A1 (0.91) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL9301664 | 0.82 | ALDH1A1 (0.61) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL8119097 | 0.80 | ALDH1A1 (0.68) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL15124759 | 0.80 | LMNA (0.63) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL13212241 | 0.78 | POLB (0.64) | ALDH1A1LMNAKDM4ETDP1SMN1; SMN2 | |
| SCHEMBL3066836 | 0.78 | LMNA (0.79) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL183995 | 0.77 | ALDH1A1 (0.72) | ALDH1A1LMNAKDM4ECYP2C9EDNRA | |
| SCHEMBL13180843 | 0.77 | ALDH1A1 (0.72) | ALDH1A1LMNAKDM4ECYP2C9EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236833-B2 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236833-B2 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236833-B2 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1934191-B1 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1934191-B1 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100130548-A1 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130548-A1 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130548-A1 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-27 | — | — | US | disclosed |
| US-7683083-B2 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683083-B2 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683083-B2 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1934191-A2 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-05-15 | — | — | US | disclosed |
| WO-2007047474-A2 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047474-A2 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130548-A1 | BIPHENYL DERIVATIVES AS MODULATORS OF VOLTAGE GATED ION CHANNELS | TRPV1, TRPA1, TRPV2 | ALDH1A1 1636/4885LMNA 3741/4885KDM4E 2475/4885 |
| US-20080113990-A1 | Biphenyl derivatives as modulators of voltage gated ion channels | TRPV1, TRPA1, TRPV2 | ALDH1A1 1636/4885LMNA 3741/4885KDM4E 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.